Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors

NCT06022276 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor
EGFR Amplification

Interventions

DRUG: Nimotuzumab

Sponsor

Tianjin Medical University Second Hospital